TG
VRTX icon

TCW Group’s Vertex Pharmaceuticals VRTX Stock Holding History

TCW Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Buy
4,266
+75
+2% +$33.2K 0.01% 281
2026
Q1 		$1.87M Buy
4,191
+203
+5% +$94.7K 0.01% 289
2025
Q4 		$1.81M Buy
+3,988
New +$1.72M 0.01% 286
2021
Q2 		– Sell
-11,981
Closed -$2.58M – 362
2021
Q1 		$2.58M Buy
11,981
+6
+0.1% +$1.32K 0.02% 241
2020
Q4 		$2.83M Buy
+11,975
New +$2.75M 0.02% 226
2017
Q1 		– Sell
-25,035
Closed -$1.84M – 615
2016
Q4 		$1.84M Hold
25,035
– – 0.01% 370
2016
Q3 		$2.18M Sell
25,035
-1,608
-6% -$152K 0.02% 312
2016
Q2 		$2.29M Buy
26,643
+750
+3% +$64.8K 0.02% 299
2016
Q1 		$2.06M Sell
25,893
-320
-1% -$28.9K 0.02% 331
2015
Q4 		$3.3M Buy
26,213
+670
+3% +$80.9K 0.02% 259
2015
Q3 		$2.66M Sell
25,543
-2,250
-8% -$289K 0.02% 292
2015
Q2 		$3.43M Sell
27,793
-51,711
-65% -$6.52M 0.02% 294
2015
Q1 		$9.38M Buy
79,504
+2,361
+3% +$283K 0.05% 261
2014
Q4 		$9.16M Sell
77,143
-48,350
-39% -$5.45M 0.04% 279
2014
Q3 		$14.1M Sell
125,493
-1,750
-1% -$167K 0.06% 259
2014
Q2 		$12M Buy
127,243
+3,900
+3% +$273K 0.05% 301
2014
Q1 		$8.72M Sell
123,343
-4,800
-4% -$380K 0.04% 359
2013
Q4 		$9.52M Buy
128,143
+245
+0.2% +$17.1K 0.04% 340
2013
Q3 		$9.7M Buy
127,898
+114,925
+886% +$9.15M 0.04% 316
2013
Q2 		$1.04M Buy
+12,973
New +$955K 0.01% 677

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TCW Group's VRTX Position: Q2 2026 in Review

TCW Group increased its Vertex Pharmaceuticals (VRTX) stake by 1.8% in Q2 2026, buying an estimated $33.2K and bringing the position to 4,266 shares worth $2.12M. The position accounts for 0.01% of the portfolio, ranked #281.

TCW Group first reported a position in VRTX in Q2 2013 and has held it in 20 quarters since. The position peaked at $14.1M in Q3 2014. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • TCW Group held 4,266 shares of Vertex Pharmaceuticals worth $2.12M as of Q2 2026.
  • TCW Group bought 75 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.2K.
  • Vertex Pharmaceuticals made up 0.01% of TCW Group's portfolio in Q2 2026, its #281 holding.
  • TCW Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 20 quarters since.
  • TCW Group's Vertex Pharmaceuticals position peaked at $14.1M in Q3 2014.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on TCW Group's 13F filing for Q2 2026, filed 3 Aug 2026.